

Calcipressin 3 (DSCR1L2) Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP6317a**Specification**

Calcipressin 3 (DSCR1L2) Antibody (C-term) Blocking peptide - Product InformationPrimary Accession [Q9UKA8](#)**Calcipressin 3 (DSCR1L2) Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 11123**Other Names**

Calcipressin-3, Down syndrome candidate region 1-like protein 2, Myocyte-enriched calcineurin-interacting protein 3, MCIP3, Regulator of calcineurin 3, RCAN3, DSCR1L2

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6317a](/product/products/AP6317a) was selected from the C-term region of human DSCR1L2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Calcipressin 3 (DSCR1L2) Antibody (C-term) Blocking peptide - Protein Information**Name** RCAN3**Synonyms** DSCR1L2**Function**

Inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A. Could play a role during central nervous system development (By similarity).

Tissue Location

Highest expression in heart, skeletal muscle kidney, liver and peripheral blood leukocytes. Lower expression in all other tissues

Calcipressin 3 (DSCR1L2) Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

Calcipressin 3 (DSCR1L2) Antibody (C-term) Blocking peptide - Images

Calcipressin 3 (DSCR1L2) Antibody (C-term) Blocking peptide - Background

DSCR1L2 inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A, and may play a role during central nervous system development. Highest expression occurs in heart, skeletal muscle kidney, liver and peripheral blood leukocytes.

Calcipressin 3 (DSCR1L2) Antibody (C-term) Blocking peptide - References

Strippoli, P., et al., Genomics 64(3):252-263 (2000).